CRISPR technology for genome editing
CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.
Advancing the science of cancer diagnosis
Learn how we are advancing the science of cancer diagnosis, and making biopsies easier for patients, through the diagnosis of circulating tumour DNA in blood samples.
AstraZeneca, designs for new Cambridge site
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca, Science newsreel
We are a global, innovation-driven biopharmaceutical business. We push the boundaries of science to deliver medicines that transform the lives of people around the world.
AstraZeneca, R&D Mölndal and Manufacturing Södertälje
Mölndal, Sweden is one of our three strategic global R&D centres with connections to Karolinska Institutet and Medicon Valley. Södertälje is one of our principal small molecule manufacturing facilities.
AstraZeneca Research & Development, Sweden
AstraZeneca, Macclesfield manufacturing
Macclesfield, in the north-west of England, is our second largest global manufacturing site and our European centre for packing. In 2013 we announced plans to invest $190 million to construct a new facility to continue production of Zoladex.
AstraZeneca, MedImmune biologics science unit Cambridge
MedImmune, our biotech unit focusing on innovation and discovery research in biologics, has an estabished presence within Cambridge. In June 2013, we confirmed that our new UK-based global R&D centre and corporate headquarters will be located at the Cambridge Biomedical Campus with a planned investment of around $515 million and is expected to be completed by 2016.